Dawn L Hershman1, Joseph M Unger2,3, Grace Clarke Hillyer1, Anna Moseley2,3, Kathryn B Arnold2,3, Shaker R Dakhil4, Benjamin T Esparaz5, Ming C Kuan6, Mark L Graham7, Douglas M Lackowski8, William J Edenfield9, Zoneddy R Dayao10, N Lynn Henry11, Julie R Gralow12, Scott D Ramsey3, Alfred I Neugut1. 1. Columbia University Medical Center, New York, NY. 2. SWOG Statistics and Data Management Center, Seattle, WA. 3. Fred Hutchinson Cancer Research Center, Seattle, WA. 4. Wichita NCORP/Cancer Center of Kansas - Wichita, Wichita, KS. 5. Heartland NCORP/Cancer Care Specialist of Central Illinois, Decatur, IL. 6. Kaiser Permanente NCORP/Kaiser Permanente NCAL, San Leandro, CA. 7. Southeast COR NCORP/Waverly Hematology/Oncology, Cary, NC. 8. Northwest NCORP/Central Interstate Medical Office Department Hematology/Oncology, Portland, OR. 9. NCORP of the Carolinas (Greenville Health System), Greenville, SC. 10. New Mexico Minority Underserved NCORP/University of New Mexico Cancer Center, Albuquerque, NM. 11. University of Michigan, Ann Arbor, MI. 12. Seattle Cancer Care Alliance/University of Washington, Seattle, WA.
Abstract
PURPOSE: Nonadherence to aromatase inhibitors (AIs) for breast cancer is common and increases the risk of recurrence. Text messaging increases adherence to medications for chronic conditions. METHODS: We conducted a randomized clinical trial of text messaging (TM) versus no text messaging (No-TM) at 40 sites in the United States. Eligible patients were postmenopausal women with early-stage breast cancer taking an AI for > 30 days with a planned duration of ≥ 36 months. Test messages were sent twice a week over 36 months. Content themes focused on overcoming barriers to medication adherence and included cues to action, statements related to medication efficacy, and reinforcements of the recommendation to take AIs. Both groups were assessed every 3 months. The primary outcome was time to adherence failure (AF), where AF was defined as urine AI metabolite assay results satisfying one of the following: < 10 ng/mL, undetectable, or no submitted specimen. A stratified log-rank test was conducted. Multiple sensitivity analyses were performed. RESULTS: In total, 724 patients were registered between May 2012 and September 2013, among whom,702 patients (348 in the text-messaging arm and 354 in the no-text-messaging arm) were eligible at baseline. Observed adherence at 36 months was 55.5% for TM and 55.4% for No-TM. The primary analysis showed no difference in time to AF by arm (3-year AF: 81.9% TM v 85.6% No-TM; HR, 0.89 [95% CI, 0.76 to 1.05]; P = .18). Multiple time to AF sensitivity analyses showed similar nonsignificant results. Three-year self-reported time to AF (10.4% v 10.3%; HR, 1.16 [95% CI, 0.69 to 1.98]; P = .57) and site-reported time to AF (21.9% v 18.9%; HR, 1.31 [95% CI, 0.86 to 2.01]; P = .21) also did not differ by arm. CONCLUSION: To our knowledge, this was the first large, long-term, randomized trial of an intervention directed at improving AI adherence. We found high rates of AI AF. Twice-weekly text reminders did not improve adherence to AIs. Improving long-term adherence will likely require personalized and sustained behavioral interventions.
PURPOSE: Nonadherence to aromatase inhibitors (AIs) for breast cancer is common and increases the risk of recurrence. Text messaging increases adherence to medications for chronic conditions. METHODS: We conducted a randomized clinical trial of text messaging (TM) versus no text messaging (No-TM) at 40 sites in the United States. Eligible patients were postmenopausal women with early-stage breast cancer taking an AI for > 30 days with a planned duration of ≥ 36 months. Test messages were sent twice a week over 36 months. Content themes focused on overcoming barriers to medication adherence and included cues to action, statements related to medication efficacy, and reinforcements of the recommendation to take AIs. Both groups were assessed every 3 months. The primary outcome was time to adherence failure (AF), where AF was defined as urine AI metabolite assay results satisfying one of the following: < 10 ng/mL, undetectable, or no submitted specimen. A stratified log-rank test was conducted. Multiple sensitivity analyses were performed. RESULTS: In total, 724 patients were registered between May 2012 and September 2013, among whom,702 patients (348 in the text-messaging arm and 354 in the no-text-messaging arm) were eligible at baseline. Observed adherence at 36 months was 55.5% for TM and 55.4% for No-TM. The primary analysis showed no difference in time to AF by arm (3-year AF: 81.9% TM v 85.6% No-TM; HR, 0.89 [95% CI, 0.76 to 1.05]; P = .18). Multiple time to AF sensitivity analyses showed similar nonsignificant results. Three-year self-reported time to AF (10.4% v 10.3%; HR, 1.16 [95% CI, 0.69 to 1.98]; P = .57) and site-reported time to AF (21.9% v 18.9%; HR, 1.31 [95% CI, 0.86 to 2.01]; P = .21) also did not differ by arm. CONCLUSION: To our knowledge, this was the first large, long-term, randomized trial of an intervention directed at improving AI adherence. We found high rates of AI AF. Twice-weekly text reminders did not improve adherence to AIs. Improving long-term adherence will likely require personalized and sustained behavioral interventions.
Authors: Melissa S Stockwell; Elyse Olshen Kharbanda; Raquel Andres Martinez; Celibell Y Vargas; David K Vawdrey; Stewin Camargo Journal: JAMA Date: 2012-04-25 Impact factor: 56.272
Authors: Dawn L Hershman; Jennifer Tsui; Jay Meyer; Sherry Glied; Grace Clarke Hillyer; Jason D Wright; Alfred I Neugut Journal: J Natl Cancer Inst Date: 2014-10-27 Impact factor: 13.506
Authors: Dawn L Hershman; Lawrence H Kushi; Theresa Shao; Donna Buono; Aaron Kershenbaum; Wei-Yann Tsai; Louis Fehrenbacher; Scarlett Lin Gomez; Sunita Miles; Alfred I Neugut Journal: J Clin Oncol Date: 2010-06-28 Impact factor: 44.544
Authors: Christos Markopoulos; Patrick Neven; Minna Tanner; Michael Marty; Rolf Kreienberg; Louise Atkins; Ann Franquet; Michael Gnant; Silvia Neciosup; Petra Tesarova; Sandro Barni; Veronique Deschamp Journal: Future Oncol Date: 2015 Impact factor: 3.404
Authors: P Hadji; M Blettner; N Harbeck; C Jackisch; H-J Lück; C Windemuth-Kieselbach; S Zaun; R Kreienberg Journal: Ann Oncol Date: 2013-02-01 Impact factor: 32.976
Authors: Jay Thakkar; Rahul Kurup; Tracey-Lea Laba; Karla Santo; Aravinda Thiagalingam; Anthony Rodgers; Mark Woodward; Julie Redfern; Clara K Chow Journal: JAMA Intern Med Date: 2016-03 Impact factor: 21.873
Authors: Jacquie H Chirgwin; Anita Giobbie-Hurder; Alan S Coates; Karen N Price; Bent Ejlertsen; Marc Debled; Richard D Gelber; Aron Goldhirsch; Ian Smith; Manuela Rabaglio; John F Forbes; Patrick Neven; István Láng; Marco Colleoni; Beat Thürlimann Journal: J Clin Oncol Date: 2016-05-23 Impact factor: 44.544
Authors: Alfred I Neugut; Xiaobo Zhong; Jason D Wright; Melissa Accordino; Jingyan Yang; Dawn L Hershman Journal: JAMA Oncol Date: 2016-10-01 Impact factor: 31.777
Authors: Sofia F Garcia; Robert J Gray; Joseph A Sparano; Amye J Tevaarwerk; Ruth C Carlos; Betina Yanez; Ilana F Gareen; Timothy J Whelan; George W Sledge; David Cella; Lynne I Wagner Journal: Cancer Date: 2021-10-06 Impact factor: 6.860
Authors: Sarah M Belcher; Emily Mackler; Benyam Muluneh; Pamela K Ginex; Mary K Anderson; Elizabeth Bettencourt; Ryan K DasGupta; Jennifer Elliott; Erica Hall; Michelle Karlin; Diana Kostoff; Victoria K Marshall; Vanessa E Millisor; Maegan Molnar; Susan M Schneider; Janelle Tipton; Susan Yackzan; Kristine B LeFebvre; Kapeena Sivakumaran; Haya Waseem; Rebecca L Morgan Journal: Oncol Nurs Forum Date: 2022-06-17 Impact factor: 1.803
Authors: Lynne I Wagner; Janet A Tooze; Daniel L Hall; Beverly J Levine; Jennifer Beaumont; Jenna Duffecy; David Victorson; William Gradishar; Joseph Leach; Thomas Saphner; Keren Sturtz; Mary Lou Smith; Frank Penedo; David C Mohr; David Cella Journal: J Natl Cancer Inst Date: 2021-11-02 Impact factor: 11.816
Authors: Dawn L Hershman; Alfred I Neugut; Anna Moseley; Kathryn B Arnold; Julie R Gralow; N Lynn Henry; Grace Clarke Hillyer; Scott D Ramsey; Joseph M Unger Journal: J Natl Cancer Inst Date: 2021-08-02 Impact factor: 11.816
Authors: Betina Yanez; Robert J Gray; Joseph A Sparano; Ruth C Carlos; Gelareh Sadigh; Sofia F Garcia; Ilana F Gareen; Timothy J Whelan; George W Sledge; David Cella; Lynne I Wagner Journal: JAMA Oncol Date: 2021-06-17 Impact factor: 33.006
Authors: Eng Hooi Tan; Andrea Li Ann Wong; Chuan Chien Tan; Patrick Wong; Sing Huang Tan; Li En Yvonne Ang; Siew Eng Lim; Wan Qin Chong; Jingshan Ho; Soo Chin Lee; Bee Choo Tai Journal: Breast Date: 2020-07-02 Impact factor: 4.380
Authors: Daniel L Hertz; Karen Lisa Smith; Yuhua Zong; Christina L Gersch; Andrea M Pesch; Jennifer Lehman; Amanda L Blackford; N Lynn Henry; Kelley M Kidwell; James M Rae; Vered Stearns Journal: Front Genet Date: 2021-06-15 Impact factor: 4.599
Authors: Maurice J Berkowitz; Carlie K Thompson; Laura T Zibecchi; Minna K Lee; Elani Streja; Jacob S Berkowitz; Cachet M Wenziger; Jennifer L Baker; Maggie L DiNome; Deanna J Attai Journal: J Cancer Surviv Date: 2020-08-17 Impact factor: 4.062